Sonnet BioTherapeutics Holdings, Inc. Common Stock (SONN)
Sonnet BioTherapeutics Holdings, Inc. is a biotechnology company focused on developing novel therapies based on its proprietary peptide platform. The company's mission is to create targeted, effective treatments for a range of diseases, including cancers and autoimmune disorders, by leveraging innovative peptide technology to enhance drug delivery and efficacy.
Company News
Sonnet BioTherapeutics, a clinical-stage oncology company, will present at the MedInvest Biotech & Pharma Conference. The company is developing immunotherapeutic drugs using its FHAB platform, with lead program SON-1010 being studied for ovarian cancer treatment in collaboration with Roche.
Law firm Monteverde & Associates is investigating potential legal actions related to merger transactions involving Sonnet BioTherapeutics, Skechers, First Community Corporation, and Signature Bank of Georgia.
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
Hot penny stocks to buy under $1 The post Best Penny Stocks to Buy Under $1? 7 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.